Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 5/20 | 0.32 |
| ▸ | CCNC | P24863 | 3/20 | 0.32 |
| ▸ | CDK8 | P49336 | 3/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945987 | 0.92 | HRH3 (0.37) | MDM2HRH3ADORA3MAPTRECQL | |
| SCHEMBL1920193 | 0.87 | TACR3 (0.34) | MDM2HRH3EIF4A3TACR3 | |
| SCHEMBL1919618 | 0.85 | MC4R (0.44) | — | |
| SCHEMBL1947860 | 0.84 | TACR3 (0.40) | MDM2EIF4A3TACR3 | |
| SCHEMBL12536338 | 0.83 | ENPP2 (0.37) | MDM2HRH3CCNCCDK8 | |
| SCHEMBL1920195 | 0.81 | MC4R (0.37) | HRH3CCNCCDK8 | |
| SCHEMBL12536340 | 0.81 | MC4R (0.38) | MDM2HRH3CCNCCDK8 | |
| SCHEMBL733358 | 0.80 | HRH3 (0.35) | HRH3 | |
| SCHEMBL1920545 | 0.80 | HRH3 (0.35) | HRH3 | |
| SCHEMBL14700307 | 0.80 | HRH3 (0.35) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592403-B2 | Diazepine and diazocane compounds as MC4 agonists | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2326638-B9 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-11-13 | — | — | EP | disclosed |
| EP-2326638-B1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | MDM2 1989/4885HRH3 37/4885ADORA3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.